TY - JOUR JO - Gastroenterology Review/Przegląd Gastroenterologiczny SN - 1895-5770 VL - 4 IS - 5 PY - 2009 ID - Wiśniewska-Jarosińska2009 TI - Long-term infliximab treatment in a patient with fistualizing Crohn’s disease AB - Introduction in the last decade the biological treatment directed against anti-TNF-α for Crohn’s disease improved the effectiveness of the therapy and at the same time increased the percentage of clinical remissions achieved. Anti-TNF-α therapies favourable affect clinical symptoms and reduce the inflammatory indices of the disease. However, the long-term biological treatment carries the risk of the loss of response and adverse events, which sometimes can be very serious. Among these agents, infliximab – a chimeric, mouse and human, monoclonal antibody, has been used in the treatment of active Crohn’s disease for the longest time. Presenting a case report of a young woman with fistualizing Crohn’s disease the authors want to share their experience and point out the therapeutic problems, which can arise during the long-term biological treatment with anti-TNF-α agents. AU - Wiśniewska-Jarosińska, Maria AU - Wichan, Paweł AU - Chojnacki, Jan SP - 277 EP - 281 DA - 2009 UR - https://www.termedia.pl/Long-term-infliximab-treatment-in-a-patient-with-fistualizing-Crohn-8217-s-disease,41,13596,1,1.html ER -